Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2019

Open Access 01-12-2019 | Obesity | Original investigation

Good glycemic control of gestational diabetes mellitus is associated with the attenuation of future maternal cardiovascular risk: a retrospective cohort study

Authors: Enav Yefet, Naama Schwartz, Basma Sliman, Avraham Ishay, Zohar Nachum

Published in: Cardiovascular Diabetology | Issue 1/2019

Login to get access

Abstract

Background

To examine whether glycemic control of gestational diabetes mellitus (GDM) could modify the risk for future maternal metabolic and cardiovascular morbidities.

Methods

A retrospective cohort study of women with a first diagnosis of GDM who delivered between 1991 and 2011. Women were divided into groups of good and poor glycemic control, defined as a mean daily glucose of up to 95 mg/dL (N = 230) and more than 95 mg/dL (N = 216), respectively. In addition, a control group of women without GDM (N = 352) was also analyzed. The primary outcomes were the development of type 2 diabetes mellitus (T2DM), obesity, hypertension, or dyslipidemia.

Results

Mean follow-up time was 15.8 ± 5.1 years. Assessment was performed at a maternal age of 45 ± 7 years. The rates of the study outcomes in the control, GDM with good glycemic control and GDM with poor glycemic control were as follows: T2DM [19 (5.4%), 87 (38%), 127 (57%)]; hypertension [44 (13%), 42 (18%), 44 (20%)]; obesity [111 (32%), 112 (48%), 129 (58%)]; and dyslipidemia [49 (14%), 67 (29%), 106 (48%)]. Glycemic control was an independent risk factor for T2DM in multivariate Cox regression analysis (hazard ratio (HR) for poor glycemic control vs. controls 10.7 95% CI [6.0–19.0], good glycemic control vs. control HR 6.0 [3.3–10.8], and poor glycemic control vs. good glycemic control HR 1.8 [1.3–2.4]). Glycemic control was also an independent risk factor for dyslipidemia (poor glycemic control vs. controls HR 3.7 [2.3–5.8], good glycemic control vs. controls HR 2.0 [1.2–3.2], and poor glycemic control vs. good glycemic control HR 1.8 1.8 [1.3–2.6]). The fasting glucose level during oral glucose tolerance test (OGTT) was also an independent risk factor for these complications. The interaction term between glycemic control and the fasting value of the OGTT was not statistically significant, suggesting that the effect of glycemic control on the rate of future T2DM and dyslipidemia was not modified by the baseline severity of GDM.

Conclusion

GDM and especially poor glycemic control are associated with T2DM and dyslipidemia. Strict glycemic control for reducing that risk should be evaluated in prospective trials.
Literature
1.
go back to reference Hedderson MM, Ferrara A, Sacks DA. Gestational diabetes mellitus and lesser degrees of pregnancy hyperglycemia: association with increased risk of spontaneous preterm birth. Obstet Gynecol. 2003;102:850–6.PubMed Hedderson MM, Ferrara A, Sacks DA. Gestational diabetes mellitus and lesser degrees of pregnancy hyperglycemia: association with increased risk of spontaneous preterm birth. Obstet Gynecol. 2003;102:850–6.PubMed
2.
go back to reference Nachum Z, Ben Shlomo I, Weiner E, Shalev E. Twice daily versus four times daily insulin dose regimens for diabetes in pregnancy: randomised controlled trial. BMJ. 1999;319:1223–7.CrossRef Nachum Z, Ben Shlomo I, Weiner E, Shalev E. Twice daily versus four times daily insulin dose regimens for diabetes in pregnancy: randomised controlled trial. BMJ. 1999;319:1223–7.CrossRef
3.
go back to reference Langer O, Rodriguez DA, Xenakis EM, McFarland MB, Berkus MD, Arrendondo F. Intensified versus conventional management of gestational diabetes. Am J Obstet Gynecol. 1994;170:1036–46.CrossRef Langer O, Rodriguez DA, Xenakis EM, McFarland MB, Berkus MD, Arrendondo F. Intensified versus conventional management of gestational diabetes. Am J Obstet Gynecol. 1994;170:1036–46.CrossRef
4.
go back to reference Ryan DK, Haddow L, Ramaesh A, et al. Early screening and treatment of gestational diabetes in high-risk women improves maternal and neonatal outcomes: a retrospective clinical audit. Diabetes Res Clin Pract. 2018;144:294–301.CrossRef Ryan DK, Haddow L, Ramaesh A, et al. Early screening and treatment of gestational diabetes in high-risk women improves maternal and neonatal outcomes: a retrospective clinical audit. Diabetes Res Clin Pract. 2018;144:294–301.CrossRef
5.
go back to reference Bellamy L, Casas JP, Hingorani AD, Williams D. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet. 2009;373:1773–9.CrossRef Bellamy L, Casas JP, Hingorani AD, Williams D. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet. 2009;373:1773–9.CrossRef
6.
go back to reference Shah BR, Retnakaran R, Booth GL. Increased risk of cardiovascular disease in young women following gestational diabetes mellitus. Diabetes Care. 2008;31:1668–9.CrossRef Shah BR, Retnakaran R, Booth GL. Increased risk of cardiovascular disease in young women following gestational diabetes mellitus. Diabetes Care. 2008;31:1668–9.CrossRef
7.
go back to reference Noctor E, Crowe C, Carmody LA, et al. ATLANTIC-DIP: prevalence of metabolic syndrome and insulin resistance in women with previous gestational diabetes mellitus by International Association of Diabetes in Pregnancy Study Groups criteria. Acta Diabetol. 2015;52:153–60.CrossRef Noctor E, Crowe C, Carmody LA, et al. ATLANTIC-DIP: prevalence of metabolic syndrome and insulin resistance in women with previous gestational diabetes mellitus by International Association of Diabetes in Pregnancy Study Groups criteria. Acta Diabetol. 2015;52:153–60.CrossRef
8.
go back to reference Lauenborg J, Mathiesen E, Hansen T, et al. The prevalence of the metabolic syndrome in a danish population of women with previous gestational diabetes mellitus is three-fold higher than in the general population. J Clin Endocrinol Metab. 2005;90:4004–10.CrossRef Lauenborg J, Mathiesen E, Hansen T, et al. The prevalence of the metabolic syndrome in a danish population of women with previous gestational diabetes mellitus is three-fold higher than in the general population. J Clin Endocrinol Metab. 2005;90:4004–10.CrossRef
9.
go back to reference Kramer CK, Campbell S, Retnakaran R. Gestational diabetes and the risk of cardiovascular disease in women: a systematic review and meta-analysis. Diabetologia. 2019;62:905–14.CrossRef Kramer CK, Campbell S, Retnakaran R. Gestational diabetes and the risk of cardiovascular disease in women: a systematic review and meta-analysis. Diabetologia. 2019;62:905–14.CrossRef
10.
go back to reference Schwartz N, Green MS, Yefet E, Nachum Z. Postprandial glycemic control during gestational diabetes pregnancy predicts the risk of recurrence. Sci Rep. 2018;8:6350.CrossRef Schwartz N, Green MS, Yefet E, Nachum Z. Postprandial glycemic control during gestational diabetes pregnancy predicts the risk of recurrence. Sci Rep. 2018;8:6350.CrossRef
11.
go back to reference Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988–1994. Arch Intern Med. 2003;163:427–36.CrossRef Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988–1994. Arch Intern Med. 2003;163:427–36.CrossRef
12.
go back to reference Xu Y, Shen S, Sun L, Yang H, Jin B, Cao X. Metabolic syndrome risk after gestational diabetes: a systematic review and meta-analysis. PLoS ONE. 2014;9:e87863.CrossRef Xu Y, Shen S, Sun L, Yang H, Jin B, Cao X. Metabolic syndrome risk after gestational diabetes: a systematic review and meta-analysis. PLoS ONE. 2014;9:e87863.CrossRef
13.
go back to reference Carpenter MW, Coustan DR. Criteria for screening tests for gestational diabetes. Am J Obstet Gynecol. 1982;144:768–73.CrossRef Carpenter MW, Coustan DR. Criteria for screening tests for gestational diabetes. Am J Obstet Gynecol. 1982;144:768–73.CrossRef
14.
go back to reference National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes. 1979;28:1039–57.CrossRef National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes. 1979;28:1039–57.CrossRef
15.
go back to reference Mizrahi S, Cohen N. Privatization through centralization in the Israeli health care system the case of the national health insurance law and its amendments. Adm Soc. 2012;44(4):412–37.CrossRef Mizrahi S, Cohen N. Privatization through centralization in the Israeli health care system the case of the national health insurance law and its amendments. Adm Soc. 2012;44(4):412–37.CrossRef
16.
go back to reference Ford ES, Li C, Zhao G. Prevalence and correlates of metabolic syndrome based on a harmonious definition among adults in the US. J Diabetes. 2010;2:180–93.CrossRef Ford ES, Li C, Zhao G. Prevalence and correlates of metabolic syndrome based on a harmonious definition among adults in the US. J Diabetes. 2010;2:180–93.CrossRef
17.
go back to reference Ito Y, Shibuya M, Hosokawa S, et al. Indicators of the need for insulin treatment and the effect of treatment for gestational diabetes on pregnancy outcomes in Japan. Endocr J. 2016;63:231–7.CrossRef Ito Y, Shibuya M, Hosokawa S, et al. Indicators of the need for insulin treatment and the effect of treatment for gestational diabetes on pregnancy outcomes in Japan. Endocr J. 2016;63:231–7.CrossRef
18.
go back to reference Mitra S, Nayak PK, Sahoo J, et al. Predictors for antenatal insulin requirement in gestational diabetes. Gynecol Endocrinol. 2014;30:565–8.CrossRef Mitra S, Nayak PK, Sahoo J, et al. Predictors for antenatal insulin requirement in gestational diabetes. Gynecol Endocrinol. 2014;30:565–8.CrossRef
19.
go back to reference O’Sullivan JB. Body weight and subsequent diabetes mellitus. JAMA. 1982;248:949–52.CrossRef O’Sullivan JB. Body weight and subsequent diabetes mellitus. JAMA. 1982;248:949–52.CrossRef
20.
go back to reference Retnakaran R, Shah BR. Mild glucose intolerance in pregnancy and risk of cardiovascular disease: a population-based cohort study. CMAJ. 2009;181:371–6.CrossRef Retnakaran R, Shah BR. Mild glucose intolerance in pregnancy and risk of cardiovascular disease: a population-based cohort study. CMAJ. 2009;181:371–6.CrossRef
21.
go back to reference Retnakaran R, Qi Y, Connelly PW, Sermer M, Zinman B, Hanley AJ. Glucose intolerance in pregnancy and postpartum risk of metabolic syndrome in young women. J Clin Endocrinol Metab. 2010;95:670–7.CrossRef Retnakaran R, Qi Y, Connelly PW, Sermer M, Zinman B, Hanley AJ. Glucose intolerance in pregnancy and postpartum risk of metabolic syndrome in young women. J Clin Endocrinol Metab. 2010;95:670–7.CrossRef
22.
go back to reference Kramer CK, Swaminathan B, Hanley AJ, et al. Each degree of glucose intolerance in pregnancy predicts distinct trajectories of beta-cell function, insulin sensitivity, and glycemia in the first 3 years postpartum. Diabetes Care. 2014;37:3262–9.CrossRef Kramer CK, Swaminathan B, Hanley AJ, et al. Each degree of glucose intolerance in pregnancy predicts distinct trajectories of beta-cell function, insulin sensitivity, and glycemia in the first 3 years postpartum. Diabetes Care. 2014;37:3262–9.CrossRef
23.
go back to reference Retnakaran R, Qi Y, Connelly PW, Sermer M, Hanley AJ, Zinman B. The graded relationship between glucose tolerance status in pregnancy and postpartum levels of low-density-lipoprotein cholesterol and apolipoprotein B in young women: implications for future cardiovascular risk. J Clin Endocrinol Metab. 2010;95:4345–53.CrossRef Retnakaran R, Qi Y, Connelly PW, Sermer M, Hanley AJ, Zinman B. The graded relationship between glucose tolerance status in pregnancy and postpartum levels of low-density-lipoprotein cholesterol and apolipoprotein B in young women: implications for future cardiovascular risk. J Clin Endocrinol Metab. 2010;95:4345–53.CrossRef
24.
go back to reference Greenberg LR, Moore TR, Murphy H. Gestational diabetes mellitus: antenatal variables as predictors of postpartum glucose intolerance. Obstet Gynecol. 1995;86:97–101.CrossRef Greenberg LR, Moore TR, Murphy H. Gestational diabetes mellitus: antenatal variables as predictors of postpartum glucose intolerance. Obstet Gynecol. 1995;86:97–101.CrossRef
25.
go back to reference Bo S, Monge L, Macchetta C, et al. Prior gestational hyperglycemia: a long-term predictor of the metabolic syndrome. J Endocrinol Invest. 2004;27:629–35.CrossRef Bo S, Monge L, Macchetta C, et al. Prior gestational hyperglycemia: a long-term predictor of the metabolic syndrome. J Endocrinol Invest. 2004;27:629–35.CrossRef
26.
go back to reference Grandi SM, Filion KB, Yoon S, et al. Cardiovascular disease-related morbidity and mortality in women with a history of pregnancy complications. Circulation. 2019;139:1069–79.CrossRef Grandi SM, Filion KB, Yoon S, et al. Cardiovascular disease-related morbidity and mortality in women with a history of pregnancy complications. Circulation. 2019;139:1069–79.CrossRef
27.
go back to reference Bassily E, Bell C, Verma S, Patel N, Patel A. Significance of obstetrical history with future cardiovascular disease risk. Am J Med. 2018;132:567–71.CrossRef Bassily E, Bell C, Verma S, Patel N, Patel A. Significance of obstetrical history with future cardiovascular disease risk. Am J Med. 2018;132:567–71.CrossRef
28.
go back to reference Mehmood S, Ye C, Connelly PW, Hanley AJ, Zinman B, Retnakaran R. Rising plasminogen activator inhibitor-1 and hypoadiponectinemia characterize the cardiometabolic biomarker profile of women with recent gestational diabetes. Cardiovasc Diabetol. 2018;17:133.CrossRef Mehmood S, Ye C, Connelly PW, Hanley AJ, Zinman B, Retnakaran R. Rising plasminogen activator inhibitor-1 and hypoadiponectinemia characterize the cardiometabolic biomarker profile of women with recent gestational diabetes. Cardiovasc Diabetol. 2018;17:133.CrossRef
29.
go back to reference Vilmi-Kerala T, Lauhio A, Tervahartiala T, et al. Subclinical inflammation associated with prolonged TIMP-1 upregulation and arterial stiffness after gestational diabetes mellitus: a hospital-based cohort study. Cardiovasc Diabetol. 2017;16:49.CrossRef Vilmi-Kerala T, Lauhio A, Tervahartiala T, et al. Subclinical inflammation associated with prolonged TIMP-1 upregulation and arterial stiffness after gestational diabetes mellitus: a hospital-based cohort study. Cardiovasc Diabetol. 2017;16:49.CrossRef
30.
go back to reference Lekva T, Michelsen AE, Aukrust P, Henriksen T, Bollerslev J, Ueland T. Leptin and adiponectin as predictors of cardiovascular risk after gestational diabetes mellitus. Cardiovasc Diabetol. 2017;16:5.CrossRef Lekva T, Michelsen AE, Aukrust P, Henriksen T, Bollerslev J, Ueland T. Leptin and adiponectin as predictors of cardiovascular risk after gestational diabetes mellitus. Cardiovasc Diabetol. 2017;16:5.CrossRef
31.
go back to reference Osman MW, Nath M, Khalil A, Webb DR, Robinson TG, Mousa HA. Haemodynamic differences amongst women who were screened for gestational diabetes in comparison to healthy controls. Pregnancy Hypertens. 2018;14:23–8.CrossRef Osman MW, Nath M, Khalil A, Webb DR, Robinson TG, Mousa HA. Haemodynamic differences amongst women who were screened for gestational diabetes in comparison to healthy controls. Pregnancy Hypertens. 2018;14:23–8.CrossRef
32.
go back to reference Timpka S, Markovitz A, Schyman T, et al. Midlife development of type 2 diabetes and hypertension in women by history of hypertensive disorders of pregnancy. Cardiovasc Diabetol. 2018;17:124.CrossRef Timpka S, Markovitz A, Schyman T, et al. Midlife development of type 2 diabetes and hypertension in women by history of hypertensive disorders of pregnancy. Cardiovasc Diabetol. 2018;17:124.CrossRef
33.
go back to reference Clark CM Jr, Qiu C, Amerman B, et al. Gestational diabetes: should it be added to the syndrome of insulin resistance? Diabetes Care. 1997;20:867–71.CrossRef Clark CM Jr, Qiu C, Amerman B, et al. Gestational diabetes: should it be added to the syndrome of insulin resistance? Diabetes Care. 1997;20:867–71.CrossRef
34.
go back to reference Martin U, Davies C, Hayavi S, Hartland A, Dunne F. Is normal pregnancy atherogenic? Clin Sci (Lond). 1999;96:421–5.CrossRef Martin U, Davies C, Hayavi S, Hartland A, Dunne F. Is normal pregnancy atherogenic? Clin Sci (Lond). 1999;96:421–5.CrossRef
35.
go back to reference Gelaleti RB, Damasceno DC, Lima PH, et al. Oxidative DNA damage in diabetic and mild gestational hyperglycemic pregnant women. Diabetol Metab Syndr. 2015;7:1.CrossRef Gelaleti RB, Damasceno DC, Lima PH, et al. Oxidative DNA damage in diabetic and mild gestational hyperglycemic pregnant women. Diabetol Metab Syndr. 2015;7:1.CrossRef
36.
go back to reference Colicchia LC, Parviainen K, Chang JC. Social contributors to glycemic control in gestational diabetes mellitus. Obstet Gynecol. 2016;128:1333–9.CrossRef Colicchia LC, Parviainen K, Chang JC. Social contributors to glycemic control in gestational diabetes mellitus. Obstet Gynecol. 2016;128:1333–9.CrossRef
37.
go back to reference Kim C. Maternal outcomes and follow-up after gestational diabetes mellitus. Diabet Med. 2014;31:292–301.CrossRef Kim C. Maternal outcomes and follow-up after gestational diabetes mellitus. Diabet Med. 2014;31:292–301.CrossRef
38.
go back to reference HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcome (HAPO) study: associations with neonatal anthropometrics. Diabetes. 2009;58:453–9.CrossRef HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcome (HAPO) study: associations with neonatal anthropometrics. Diabetes. 2009;58:453–9.CrossRef
39.
go back to reference Rudge MV, Calderon IM, Ramos MD, Abbade JF, Rugolo LM. Perinatal outcome of pregnancies complicated by diabetes and by maternal daily hyperglycemia not related to diabetes. A retrospective 10-year analysis. Gynecol Obstet Invest. 2000;50:108–12.CrossRef Rudge MV, Calderon IM, Ramos MD, Abbade JF, Rugolo LM. Perinatal outcome of pregnancies complicated by diabetes and by maternal daily hyperglycemia not related to diabetes. A retrospective 10-year analysis. Gynecol Obstet Invest. 2000;50:108–12.CrossRef
40.
go back to reference Rudge MV, Peracoli JC, Berezowski AT, Calderon IM, Brasil MA. The oral glucose tolerance test is a poor predictor of hyperglycemia during pregnancy. Braz J Med Biol Res. 1990;23:1079–89.PubMed Rudge MV, Peracoli JC, Berezowski AT, Calderon IM, Brasil MA. The oral glucose tolerance test is a poor predictor of hyperglycemia during pregnancy. Braz J Med Biol Res. 1990;23:1079–89.PubMed
41.
go back to reference Hernandez TL, Friedman JE, Van Pelt RE, Barbour LA. Patterns of glycemia in normal pregnancy: should the current therapeutic targets be challenged? Diabetes Care. 2011;34:1660–8.CrossRef Hernandez TL, Friedman JE, Van Pelt RE, Barbour LA. Patterns of glycemia in normal pregnancy: should the current therapeutic targets be challenged? Diabetes Care. 2011;34:1660–8.CrossRef
42.
go back to reference Hernandez TL. Glycemic targets in pregnancies affected by diabetes: historical perspective and future directions. Curr Diab Rep. 2015;15:565.CrossRef Hernandez TL. Glycemic targets in pregnancies affected by diabetes: historical perspective and future directions. Curr Diab Rep. 2015;15:565.CrossRef
Metadata
Title
Good glycemic control of gestational diabetes mellitus is associated with the attenuation of future maternal cardiovascular risk: a retrospective cohort study
Authors
Enav Yefet
Naama Schwartz
Basma Sliman
Avraham Ishay
Zohar Nachum
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2019
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-019-0881-6

Other articles of this Issue 1/2019

Cardiovascular Diabetology 1/2019 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.